Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma

Imagem de Miniatura
Arquivos
art_DANILOVIC_Pre_operative_role_of_BRAF_in_the_guidance_2014.PDF (114.8 KB)
Citações na Scopus
26
Tipo de produção
article
Data de publicação
2014
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
BIOSCIENTIFICA LTD
Autores
DOMINGUES, Regina B.
Citação
EUROPEAN JOURNAL OF ENDOCRINOLOGY, v.170, n.4, p.619-625, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: The p. V600E BRAF and RAS mutations are found in 30-80% of differentiated thyroid carcinoma (DTC). BRAF mutation has been associated with poor prognosis. This study investigated the role of molecular studies in preoperative diagnosis of DTC and the association of p. V600E mutation with prognostic factors. Design: Prospective study. Methods: A total of 202 patients with cytological diagnosis of Bethesda III-VI underwent preoperative molecular studies and subsequent thyroidectomy. p. V600E and RAS mutations were studied in the cytology smears, using real-time PCR genotyping technique. The BRAF mutation (BRAF(+) or BRAF(-)) was correlated with histological and clinical findings. Results: Molecular study of 172 nodules with Bethesda III-V cytology improved negative predictive value and accuracy of Bethesda III and IV diagnosis. BRAF mutation was present in 65% of 94 DTC and p. Q61R NRAS in one. Except for age, BRAF C and BRAF(1) did not differ in sex, tumor size, histological subtype, multifocality, vascular invasion, extrathyroidal extension, or prognostic staging. Among papillary carcinomas, lymph node (LN) metastasis was diagnosed in 23% BRAF C and 37% BRAF K. Distant metastasis occurred in four BRAF(-) . Recurrent or persistent disease was more frequent in BRAF K (26.7 vs 3.3% BRAF(+), P=0.002) along follow-up of 29.8 +/- 10 months. BRAF(+) patients without LN metastasis by pre-operative evaluation submitted to thyroidectomy with central neck dissection ( CND) had more frequent LN metastasis ( 45 vs 5% no CND, P=0.002), but no difference in clinical outcome was observed. Conclusions: Pre-operative identification of BRAF mutation improved cytological diagnosis of DTC, but it was not associated with poor prognostic factors. Prophylactic CND did not guarantee better outcome in BRAF C patients.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/7307
Referências
  1. Alexander EK, 2012, NEW ENGL J MED, V367, P705, DOI 10.1056/NEJMoa1203208
  2. Baloch ZW, 2008, DIAGN CYTOPATHOL, V36, P425, DOI 10.1002/dc.20830
  3. Benlloch S, 2006, J MOL DIAGN, V8, P540, DOI 10.2353/jmoldx.2006.060070
  4. Cantara S, 2010, J CLIN ENDOCR METAB, V95, P1365, DOI 10.1210/jc.2009-2103
  5. Chung KW, 2006, CLIN ENDOCRINOL, V65, P660, DOI 10.1111/j.1365-2265.2006.02646.x
  6. Cooper DS, 2009, THYROID, V19, P1167, DOI 10.1089/thy.2009.0110
  7. Dutenhefner SE, 2013, THYROID, V23, P1541, DOI 10.1089/thy.2012.0304
  8. Fugazzola L, 2006, ENDOCR-RELAT CANCER, V13, P455, DOI 10.1677/erc.1.01086
  9. Greene FL, 2002, AJCC CANC STAGING MA, P77
  10. Guerra A, 2012, J CLIN ENDOCR METAB, V97, P2333, DOI 10.1210/jc.2011-3106
  11. Guth S, 2009, EUR J CLIN INVEST, V39, P699, DOI 10.1111/j.1365-2362.2009.02162.x
  12. Hegedus L, 2004, NEW ENGL J MED, V351, P1764, DOI 10.1056/NEJMcp031436
  13. Ito Y, 2009, ENDOCR J, V56, P89
  14. Joo JY, 2012, J CLIN ENDOCR METAB, V97, P3996, DOI 10.1210/jc.2012-2444
  15. Kimura ET, 2003, CANCER RES, V63, P1454
  16. Lee KC, 2012, SURGERY, V152, P977, DOI 10.1016/j.surg.2012.08.019
  17. Li C, 2012, J CLIN ENDOCR METAB, V97, P4559, DOI 10.1210/jc.2012-2104
  18. Liu RT, 2005, CLIN ENDOCRINOL, V63, P461, DOI 10.1111/j.1365-2265.2005.02367.x
  19. Nam JK, 2012, AM J SURG, V203, P436, DOI 10.1016/j.amjsurg.2011.02.013
  20. Nikiforov YE, 2009, J CLIN ENDOCR METAB, V94, P2092, DOI 10.1210/jc.2009-0247
  21. Puxeddu E, 2004, J CLIN ENDOCR METAB, V89, P2414, DOI 10.1210/jc.2003-031425
  22. Randolph GW, 2012, THYROID, V22, P1144, DOI 10.1089/thy.2012.0043
  23. Sancisi V, 2012, J CLIN ENDOCR METAB, V97, pE1745, DOI 10.1210/jc.2012-1526
  24. Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706
  25. Trovisco V, 2008, CLIN ENDOCRINOL, V69, P683, DOI 10.1111/j.1365-2265.2008.03243.x
  26. Vince A, 1998, BRIT J HAEMATOL, V101, P349, DOI 10.1046/j.1365-2141.1998.00702.x
  27. Xing M, 2004, J CLIN ENDOCR METAB, V89, P1365, DOI 10.1210/jc.2003-031488
  28. Xing MZ, 2013, LANCET, V381, P1058, DOI 10.1016/S0140-6736(13)60109-9
  29. Zatelli MC, 2009, EUR J ENDOCRINOL, V161, P467, DOI 10.1530/EJE-09-0353

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/25
Artigos e Materiais de Revistas Científicas - LIM/28
Artigos e Materiais de Revistas Científicas - ODS/03